Kornimate/medical-research-clean huggingface dataset:
using digital health, financial incentives, and community health worker support to change health behavior

Conditions: Diabetes Mellitus

Summary: this randomized controlled trial tests how digital health monitoring with financial incentives (dfi) and community health worker (chw) support may affect how a person manages their diabetes. participants will be randomized to one of three arms: 1) dfi intervention, 2) hybrid dfi/chw intervention, or 3) usual care. investigators hypothesize that compared to usual care and dfi alone, the hybrid intervention will lead to more glucose self-monitoring and greater improvements in glycosylated hemoglobin.

low-income americans struggle to stay healthy in the face of real-life challenges such as housing insecurity or trauma. two interventions show promise for promoting behavior change and improving health outcomes: digital health interventions coupled with financial incentives (dfi) and community health workers (chws). yet, these interventions have limitations; dfi interventions have low uptake and high attrition among vulnerable populations, while chw interventions are relatively resource intensive. investigators propose a 24-week randomized trial of a hybrid dfi/chw intervention among a population of 150 low-income patients with diabetes. participants will be randomized to one of three arms: 1) dfi intervention, 2) hybrid dfi/chw intervention, 3) usual care. participants assigned to dfi will receive a free wireless glucometer and be eligible for a lottery incentive if they use their glucometer. participants assigned to the hybrid dfi/chw intervention will receive the same glucometer and incentives. if they exhibit low adherence to self-monitoring or poor glucose control, they will also receive support from a chw who would help patients to address underlying socioeconomic barriers and cope with setbacks. investigators hypothesize that compared to usual care and dfi alone, the hybrid intervention will lead to more glucose self-monitoring and greater improvements in glycosylated hemoglobin.

Eligibility criteria:
inclusion criteria: * penn medicine patients diagnosed with diabetes mellitus. * glycosylated hemoglobin \>=9% within the past 6 months. * requires insulin. * uninsured/publicly insured. * residents of high-poverty zip codes in west/southwest philadelphia. * have access to a cellphone with unlimited text message capabilities. exclusion criteria: * already have a continuous glucose monitor. * previously enrolled in the study. * currently have an outpatient chw. * unwilling/unable to provide informed consent. * in another study that asks participants to monitor their blood sugar.

Keywords: community health worker financial incentives
effectiveness of night splinting after percutaneous needle fasciotomy in dupuytren's contracture

Conditions: Dupuytren Contracture; Dupuytren's Disease

Summary: dupuytren's contracture (dc) is associated with progressive finger flexion and extension deficit caused by fibrosis in the palm and digits. treatment options include minimally invasive procedures such as percutaneous needle fasciotomy (pnf) and collagenase clostridium histolyticum injections as well as open fasciectomy. pnf has recently become more popular in sweden because it is an office-based procedure which is relatively easy to perform without the usual risks and costs of open surgery. after treatment with pnf patients usually continue with supervised rehabilitation, which includes physical therapy and night splinting. whether night splinting is beneficial in terms of reducing recurrence of dc is currently debated. this study aims to investigate whether night splinting after performed pnf helps to reduce recurrence rate or not. patients who meet the inclusion criteria will be randomized into two groups: the first group will be treated as usual with physical therapy and night splinting after pnf. the second group will be treated with physical therapy without night splinting after pnf. follow up includes physical examination regarding active range of motion, sensation and grip strength at procedure day and 2 weeks, 3, 12 and 36 months later as well as questionnaires regarding hand function, pain and quality of life at procedure day and 3, 12 and 36 months later. patients who are randomized into the second group (no night splinting) will also be examined 3 weeks after pnf for observation in case of an early impairment regarding extension deficit.


Eligibility criteria:
inclusion criteria: * 18 years of age and older, * palpable dupuytren strand with passive extension deficit according to stadium 1 and 2 of the classification of tubiana in one or two fingers excluding the thumb, defined as at least 30 degrees in the mcp joint and/or at least 20 degrees in the pip joint and a maximum of 75 degrees in the mcp or pip joint exclusion criteria: * multiple, invasive or wide strands in the palm, * skin irritation, * strand localization in the digit only, * digital nerve injury, * any former treatment for dupuytren's contracture in the same digit, * thumb contracture, * stadium 3 and 4 according to the classification of tubiana

Keywords: percutaneous needle fasciotomy splint
safety and efficacy of thiscart19 in patients with refractory or relapsed b cell malignancies

Conditions: B Cell Malignancy

Summary: this is a study to evaluate the safety and clinical activity of thiscart19 (allogeneic car-t targeting cd19) in patients with refractory or relapsed cd19 positive b cell malignancies.

this is a single-center, nonrandomized, open-label study to evaluate the safety and clinical activity of thiscart19 in patients with refractory or relapsed cd19 positive b cell malignancies, such as acute or chronic lymphocytic leukemia, lymphoma and etc. the dose range is 0.2-60 x 10\^6 cells per kg body weight.

Eligibility criteria:
inclusion criteria: 1. patient with relapsed or refractory cd19 positive acute or chronic lymphocytic leukemia, or lymphoma. 2. no alternative treatment options deemed by investigator. 3. measurable or detectble disease at time of enrollment. 4. eastern cooperative oncology group (ecog) performance status of ≤2. 5. cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as determined by an echocardiogram (echo). 6. estimated life expectancy \> 12 weeks deemed by investigator. 7. serum creatinine ≤1.6 mg/dl and/or blood urea nitrogen(bun) ≤ 1.5 mg/dl . 8. serum alanine aminotransferase (alt) and aspartate aminotransferase (ast) \< 5 upper limit of normal (uln). 9. informed consent explained to, understood by and signed by patient/guardian. exclusion criteria: 1. pregnant or lactating women 2. uncontrolled infection 3. active hepatitis b virus or hepatitis c virus infection. 4. patients who need steroids to control disease. 5. patients who accepted autologous stem-cell transplantation (asct) within 100 days. 6. patients with grade 2-4 graft-versus-host disease (gvhd), or deemed need to manage by investigator. 7. history of human immunodeficiency virus (hiv) infection. 8. patients with active central nervous system (cns) involvement by malignancy. 9. patients combine with other disease cause neutrophil count (anc) \< 750 per microlitre or platelet count (plt)\< 50,000 per microlitre.
cathelicidin ll-37 levels in the gcf and the saliva of smokers and non-smokers with stage iii,iv periodontitis

Conditions: Smoking Reduction

Summary: periodontitis is considered an inflammatory disease that results in the disruption of oral hemeostasis and is associated with the presence of dental plaque influenced by genetic and environmental factors. it is well-establised that smokers have an increased severity of periodontal disease,a higher prevalance of tooth loss and total edentulism.

antimicrobial peptides (amps) are soluble molecules participating in the innate immunity of mucosal surfaces against pathogens. dysregulated expression of amps has been considered a possible causal mechanistic link in the microbial dysbiosis associated with periodontal disease and some risk factors, including tobacco smoking, diabetes mellitus, and obesity.antimicrobial peptides as a part of innate immunity are important molecules that provide a balance between disease and health. moreover, they are considered to be an important intermediate step in initiating an initial immune response against the microbial side of the gingival epithelium and in the transition to acquired immunity. cathelicidins, in particular - which play an important role in regulating the immunological response of oral tissues, are a group of peptides released from neutrophil granules and they are present only in humans in the form of ll-37.

Eligibility criteria:
inclusion criteria: 1. presence of a minimum of 15 natural teeth. 2. at least four non-adjacent teeth sites in each jaw having cal ≥ 5 mm and pd \> 5 mm in one or more sites. 3. bleeding on probing (bop) ≥ 30%. 4. tooth loss due to periodontitis ≤ 4 teeth. 5. for smoker's patients; study will include patients who regularly smoked at least 10 cigarettes/day for a minimum of 5 years. 6. for non-smokers patients; study will include patients who had never smoked. exclusion criteria: 1. individuals with a history of systemic diseases or immunological disorders. 2. individuals using hormone replacement therapy. 3. pregnant and lactating women. 4. individuals that received periodontal treatment within the last 6 months. 5. individuals with a history of systemic antibiotics and anti-inflammatory drugs within the last 3 months.
registry of emergent large vessel occlusion due to intracranial atherosclerosis

Conditions: Intracranial Stenosis; Large Vessel Occlusion; Mechanical Thrombectomy

Summary: the aim of this study is to develop an international multicenter registry of patient data and outcomes for patients undergoing mechanical thrombectomy for emergent large vessel occlusion with residual underlying stenosis following successful revascularization.


Eligibility criteria:
inclusion criteria: * all patients undergoing mechanical thrombectomy * and have intracranial stenosis * patients aged 18-90 years exclusion criteria: * none

Keywords: intracranial stenosis large vessel occlusion
impact of chronic disease control and aging psychology on outcomes of frailty-sarcopenia syndrome in ambulatory geriatric patients

Conditions: Ambulatory Geriatric Outpatients at High Risk of Frailty

Summary: pursuant to our previous longitudinal study (clinicaltrials.gov id: nct02073370) in geriatric outpatients cooperated with the department of family medicine, department of geriatrics and gerontology, national taiwan university hospital, this study will be conducted to examine the impacts of the specific co-morbidities and ageing psychology on the outcomes of frailty/sarcopenia syndrome. the thresholds of specific chronic disease will be reviewed after frailty being considered in the elderly with co-morbidity condition. in addition, the conceptual framework and corresponding measuring instrument of "mental frailty" will be expected developed.


Eligibility criteria:
inclusion criteria : compatible one of following conditions * functional decline in recent one year * cognitive function decline * depressive symptom * mobility impairment * fall in recent one year * eating or feeding problems/weight loss * co-morbid conditions≧5 * tracking by different physician ≧3 in recent half year * polypharmacy≧8 in recent 3 months * hospitalization ≧1 in recent one year * emergency visits≧2 in recent one year * aged ≧ 80 exclusion criteria: * non-ambulatory (bed-ridden) patients * long-term residents at nursing homes * patients with a life expectancy shorter than six months * impairment in vision, hearing, or communicative ability * making convenience of clinical evaluation during the study period impossible.

Keywords: sarcopenia frailty chronic disease control aging psychology
acute effect of nitrate from natural dietary sources on arterial stiffness and blood pressures in healthy individuals

Conditions: Healthy

Summary: the purpose of this study is to evaluate the acute effect of a meal high in dietary nitrates on aortic augmentation index, brachial and aortic blood pressures, and subendocardial viability ration (sevr).

hypertension has become a common medical condition worldwide, raising public concern regarding the accompanying increase in cardiovascular disease risk and other health risks. targets for optimal blood pressure are often unmet by conventional pharmaceutical therapies; consequently, complementary and alternative medicines are increasing in popularity among patients wishing to better manage their bp. in the case of hypertension, endothelial dysfunction and cardiovascular disease, a decline in the ability of blood vessels to dilate in response to shear stress is a major contributor to vascular pathology. at the core of these conditions is a decreased ability to synthesize nitric oxide, a potent vasodilatory agent. the proposed study will examine whether or not increasing the intake of dietary nitrate, which can be converted to nitric oxide endogenously, can improve three indices of vascular function that are validated risk factors for cvd: arterial stiffness, as measured by aortic augmentation index (aix), aortic bp and brachial bp.

Eligibility criteria:
inclusion criteria: * healthy volunteers aged 18-50 * must consider themselves to be in good overall health and be free of any conditions or illnesses women must be post-menopausal or not pregnant. * body mass index (bmi) must be \<30kg/m\^2. * normotensive, as defined by brachial sbp \<140mmhg and dbp \<90mmhg * subjects must also be willing to stop using mouthwash for the duration of their participation in the study. exclusion criteria: * women of childbearing age may not be pregnant, planning to become pregnant, or breastfeeding at the time of the study * bmi \>30kg/m\^2 * hypertensive as defined by brachial sbp \>140mmhg and/or dbp \>90mmhg * allergy or sensitivity to the study product, reference therapy or nitrates * having any gastrointestinal complication or condition * chronic use of medications such as prescription nsaids, antacids, blood-thinners, hypertensive medications, medications affecting no synthesis such as viagra, and use of antibiotics within one month of the study start * individuals who are involved in another clinical trial.

Keywords: dietary nitrates arterial stiffness vascular blood pressure
the antihypercholestrolemic effect of a combined nutritional supplementation of standardized extracts of amla, walnut, red yeast rice and olive

Conditions: Hyperlipidemia

Summary: nutraceutical lipid-lowering interventions are becoming increasingly popular, particularly among patients who are intolerant or refractory to prescription statins, or who desire alternative non-conventional pharmacological treatment to manage their dyslipidaemia, whether they previously experienced statin intolerance or not. a growing body of preclinical and clinical evidence suggest that the amla (emblica officinalis) red yeast rice (ryr), olive and walnut leaf extracts posses consideable hpolipidaemic pharmacological effects.

the present exploratory study aimed to assess the safety, efficacy, and patient's satisfaction of a combined supplementation of amla, red yeast rice, olive, and walnut leaf extracts (cholesfytol ng®) on total cholesterol (tc), low-density lipoprotein - cholesterol (ldl-c), high-density lipoprotein - cholesterol (hdl-c), non-high-density lipoprotein - cholesterol (non-hdl-c), remnant cholesterol (rc) and triglycerides (tg) in hyperlipidaemic patients.

Eligibility criteria:
inclusion criteria: * age ≥ 21 years * both male or female * blood total cholesterol (tc) level ≥ 200 mg/dl * blood low-density lipoprotein cholesterol (ldl-c) level ≥ 130 mg/dl * with or without myalgia and/or diabetes * no prior treatment of cholesterol-lowering agents and/or patients whose cholesterol- lowering treatment did not allow them to reach ldl-c target * patients who had stopped their cholesterol-lowering treatment because of side effects including myalgia exclusion criteria: * pregnant nor breastfeeding patients
activating treatment as prevention through community mobilization in south africa

Conditions: HIV

Summary: the purpose of this study is to evaluate the impact of a community mobilization intervention on the uptake of hiv testing, linkage to and retention in hiv care using a community, cluster randomized trial.

eight of 16 intervention naïve communities in the agincourt hdss will be randomized to receive the cm intervention to activate tasp based on the investigators cm conceptual framework. the 16 villages will be randomized based on the "restricted randomization" approach, a stratification method to ensure overall balance between intervention and control communities. intervention activities will map onto the investigators six mobilization domains identified in the investigators preliminary work as key components for communities to mobilize for change around hiv prevention. these activities will support communities to: 1) identify a shared concern around testing, linkage and retention in care; 2) enable communities to develop critical consciousness around tasp; 3) facilitate identification and development of structures and networks to disseminate information and activities around tasp; 4) identify and engage community leadership around tasp; 5) take collection action to support tasp; and 6) build community cohesion to address the hiv epidemic and support access to care. the investigators will evaluate the impact of the intervention using a linked data set including electronic clinic records and the hdss census data, which will allow us to determine whether people in the intervention communities test at higher proportions than those in control communities, whether individuals who test positive in the intervention communities are more likely to receive cd4 testing and initiate treatment within 3 months than the control communities, and whether those who are eligible and not eligible for treatment are retained in care. the investigators will implement a representative cross-sectional survey in all 16 villages prior to and following the intervention in order to examine changes in cm domains across villages and the mechanisms through which the intervention affects hiv testing, linkage and retention. in addition, intervention progress and dosage will be carefully monitored through a tracking system to document all workshops and activities that are carried out in each village.

Eligibility criteria:
inclusion criteria: * lived in the study area for 12 months * age 18-49 years * able to provide informed consent. exclusion criteria: -
methods of improvement adherence with therapy in ulcerative colitis.

Conditions: Ulcerative Colitis

Summary: ulcerative colitis is associated with a significantly increased risk of colorectal cancer. this risk can be reduced through regular medication with 5asa compounds. their effectiveness however is limited by poor adherence to the treatment protocols by many patients. the hypothesis which underlies this proposal is that if the factors responsible for poor compliance can be identified, interventions could be developed which would help to overcome the barriers which exist in individual patients. these interventions would be based on the reasons for non-adherence, specifically tailored to the needs of the individual. as a result such interventions will improve patients' adherence with prescribed 5asa and therefore reduce the relapses of the disease and a cancer risk.

poor adherence to treatment is well recognised and significantly contributes to treatment failures. in ulcerative colitis it may be associated with an increased risk of colorectal cancer. estimates for non-adherence range from 15% to 93% with an average of around a third of patients failing to adhere to their recommended therapeutic regimen. the study aims to evaluate a wide-ranging approach to reducing poor adherence, which is based on factors associated with non-adherence and involves the patient in choosing interventions. the effectiveness of the overall intervention will be assessed through a randomised controlled trial comparing intervention against standard care.

Eligibility criteria:
inclusion criteria: * male and female patients aged 18-80. * those in whom a diagnosis of ulcerative colitis is based on histological confirmation of the disease. * patients who are on daily maintenance therapy with 5 asa medication. * patients who have read the information leaflet and voluntarily given informed consent. exclusion criteria: * those aged under 18 years old. * those with a diagnosis of crohn's disease. * patients not on regular 5asa compound as maintenance therapy. * patients unable to give informed consent. * patients who do not wish to participate in the study.

Keywords: adherence with therapy adherence enhancing intervention nonadherence ulcerative colitis
minor histocompatibility vaccination after allogeneic stem cell transplantation for advanced hematologic malignancies

Conditions: Preleukemia; Myeloproliferative Disorders; Lymphoma; Myeloma; Graft Versus Host Disease

Summary: this is a clinical research study designed to evaluate whether the administration of a vaccine to patients after transplant consisting of a minor histocompatibility antigen (mhag peptide) mixed with g-csf (a drug intended to stimulate the immune system) can stimulate increased graft versus leukemia (gvl) responses without causing graft-versus-host disease (gvhd).


Eligibility criteria:
inclusion criteria: * relapsed or refractory acute myelogenous or lymphoid leukemia. * acute myeloid or lymphocytic leukemia in first remission at high-risk for recurrence. * chronic myelogenous leukemia in accelerated phase or blast-crisis. * chronic myelogenous leukemia in second or subsequent chronic phase * recurrent or refractory malignant lymphoma or hodgkin's disease * multiple myeloma at high risk for disease recurrence. * chronic lymphocytic leukemia, relapsed or with poor prognostic features. * myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic features. exclusion criteria: * clinical progression. * contra-indications for vaccination.

Keywords: gvhd